Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Valneva completes Phase 3 trial recruitment for its inactivated COVID-19 vaccine candidate
June 9, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022